Logo

SERA

Sera Prognostics, Inc.

SERA

Sera Prognostics, Inc. • NASDAQ
$3.33 ▲ 0.30% (+0.01)
Market Cap $125.30 M
52w High $9.13
52w Low $1.37
Dividend Yield 0%
P/E -4.38
Volume 18.39K
Outstanding Shares 37.63M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $16K ▼ $8.955M ▼ $-7.814M ▲ -48.837K% ▼ $-0.16 $-7.569M ▲
Q2-2025 $17K ▼ $9.296M ▲ $-8.046M ▲ -47.329K% ▼ $-0.16 ▲ $-7.807M ▲
Q1-2025 $38K ▲ $9.248M ▼ $-8.187M ▲ -21.545K% ▲ $-0.2 ▲ $-7.967M ▲
Q4-2024 $24K ▼ $9.415M ▲ $-8.579M ▼ -35.746K% ▼ $-0.25 ▼ $-8.362M ▼
Q3-2024 $29K $8.878M $-7.919M -27.307K% $-0.24 $-7.713M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $43.304M ▲ $108.125M ▼ $25.943M ▲ $82.182M ▼
Q2-2025 $40.16M ▼ $111.828M ▼ $23.602M ▲ $88.226M ▼
Q1-2025 $46.197M ▼ $118.184M ▲ $23.401M ▼ $94.783M ▲
Q4-2024 $46.236M ▼ $72.575M ▼ $24.772M ▲ $47.803M ▼
Q3-2024 $49.752M $79.001M $24.35M $54.651M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.814M ▲ $-6.477M ▼ $5.169M ▼ $373K ▲ $-935K ▼ $-6.589M ▼
Q2-2025 $-8.046M ▲ $-5.473M ▲ $5.241M ▲ $18K ▼ $-214K ▼ $-5.754M ▲
Q1-2025 $-8.187M ▲ $-7.553M ▼ $-44.802M ▼ $53.542M ▲ $1.187M ▼ $-7.556M ▼
Q4-2024 $-8.579M ▼ $-6.26M ▲ $7.385M ▲ $234K ▲ $1.359M ▲ $-6.321M ▲
Q3-2024 $-7.919M $-6.995M $4.898M $117K $-1.98M $-7.316M

Five-Year Company Overview

Income Statement

Income Statement Sera is still a pre‑revenue, development‑stage company. Over the last several years it has not reported meaningful product sales, while continuing to record steady operating losses. The size of those losses has been relatively stable rather than rapidly worsening, which suggests some spending discipline, but the business model has not yet proven it can generate commercial revenue to offset its costs. Earnings per share remain clearly negative, consistent with a company focused on building and validating its technology rather than monetizing it at scale.

Balance Sheet

Balance Sheet The balance sheet is lean and has been shrinking since shortly after the IPO. Cash that was once a core strength has now been largely drawn down, which increases funding risk going forward. The company currently carries no meaningful debt, which reduces financial leverage risk, but shareholder equity has been eroding as losses accumulate. Overall, Sera looks undercapitalized for a biotech‑style business that still needs time and investment to reach commercial proof of concept.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting ongoing spending on research, trials, and infrastructure without offsetting revenue. Free cash flow is also negative, though capital spending appears modest, so the main cash use is operating expenses rather than big equipment or facility projects. The pattern signals a classic cash‑burn profile: the company relies on external capital (equity or other financing) to fund its activities, and with cash on hand now quite low, the need for additional funding looks increasingly time‑sensitive.

Competitive Edge

Competitive Edge Sera holds an early, specialized position in pregnancy‑related diagnostics, with its proteomics‑based PreTRM test as the flagship product. Its edge comes from being an early mover, owning proprietary biomarker panels and algorithms, and building a growing body of clinical evidence. Partnerships with large insurers and health systems add credibility and may help with adoption. However, the company is still in the early stages of commercial rollout, with reimbursement, physician behavior change, and competition from larger diagnostics players all representing real uncertainties. The moat is emerging but not yet firmly established in practice.

Innovation and R&D

Innovation and R&D Innovation is the core of Sera’s story. The company is applying proteomics and advanced analytics to predict preterm birth and other serious pregnancy complications, aiming to personalize prenatal care. R&D appears to be the primary use of resources, with a pipeline that extends beyond preterm birth to conditions like preeclampsia, gestational diabetes, stillbirth risk, fetal growth issues, due‑date accuracy, and even postpartum depression. The opportunity is significant if clinical and economic value are demonstrated at scale, but the scientific, regulatory, and adoption hurdles are substantial, and timelines can be long and unpredictable.

Summary

Sera Prognostics is a highly innovative but very early‑stage healthcare company: scientifically rich, commercially unproven, and financially constrained. Its technology and pipeline target important, underserved problems in pregnancy care and could be impactful if widely adopted. At the same time, the financial statements show no meaningful revenue, ongoing cash burn, and a dwindling cash cushion, implying dependence on future financing. The investment case hinges on whether Sera can convert its scientific and clinical advantages into broad payer coverage, physician adoption, and sustainable revenues before funding pressure becomes too acute.

NEWS

November 24, 2025 · 8:00 AM UTC

Sera Announces Publication Acceptance for PRIME Study

Read more

November 13, 2025 · 4:05 PM UTC

SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

Read more

October 30, 2025 · 4:05 PM UTC

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025

Read more

October 1, 2025 · 8:05 AM UTC

Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer

Read more